Law360, New York (May 31, 2016, 2:17 PM EDT) -- The U.S. Supreme Court on Tuesday declined to review an infringement case over the antibiotic Cubicin in which Cubist Pharmaceuticals Inc. alleged that lower courts erred in nixing the asserted claims of four of the drug's five patents by effectively creating new rules for evaluating a patent's obviousness.
The high court did not expand on its rationale for declining to review whether the District of Delaware and the Federal Circuit erred by holding that secondary considerations — such as sales figures — must be comparable in scope with an invention's claimed features so that they may be given significant weight as...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!